Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
MRK [NYSE]
Merck & Co. Inc.
IndexDJIA S&P500 P/E32.78 EPS (ttm)1.82 Insider Own0.04% Shs Outstand2.85B Perf Week1.00%
Market Cap170.08B Forward P/E16.79 EPS next Y3.55 Insider Trans-1.04% Shs Float2.85B Perf Month5.35%
Income5.39B PEG5.16 EPS next Q0.86 Inst Own75.20% Short Float0.80% Perf Quarter0.61%
Sales43.08B P/S3.95 EPS this Y-26.50% Inst Trans-1.69% Short Ratio2.18 Perf Half Y6.80%
Book/sh15.71 P/B3.80 EPS next Y1.86% ROA5.20% Target Price63.56 Perf Year26.64%
Cash/sh5.03 P/C11.85 EPS next 5Y6.35% ROE11.10% 52W Range46.55 - 60.98 Perf YTD21.93%
Dividend1.76 P/FCF30.25 EPS past 5Y-16.50% ROI6.60% 52W High-2.84% Beta0.33
Dividend %2.95% Quick Ratio1.10 Sales past 5Y13.00% Gross Margin59.70% 52W Low27.29% ATR1.02
Employees77300 Current Ratio1.30 Sales Q/Q-4.30% Oper. Margin18.10% RSI (14)53.43 Volatility1.15% 1.66%
OptionableYes Debt/Eq0.62 EPS Q/Q-18.40% Profit Margin12.50% Rel Volume0.81 Prev Close59.66
ShortableYes LT Debt/Eq0.41 EarningsOct 27 BMO Payout94.60% Avg Volume10.44M Price59.25
Recom2.50 SMA200.91% SMA501.43% SMA2003.73% Volume8,410,863 Change-0.69%
Apr-30-14Reiterated Argus Buy $62 → $66
Apr-11-14Reiterated MKM Partners Buy $64 → $70
Feb-05-14Reiterated Argus Buy $54 → $62
Jan-14-14Reiterated MKM Partners Buy $59 → $64
Jun-03-13Reiterated MKM Partners Buy $54 → $59
Apr-15-13Reiterated Barclays Overweight $45 → $60
Feb-04-13Reiterated MKM Partners Buy $51 → $52
Feb-04-13Reiterated Barclays Overweight $46 → $45
Nov-20-12Upgrade MKM Partners Neutral → Buy $47 → $51
Oct-17-12Reiterated MP Advisors Outperform $45 → $50
Jul-30-12Reiterated UBS Buy $45 → $50
Jul-13-12Upgrade MP Advisors Market Perform → Outperform $45
Feb-03-12Reiterated Barclays Capital Overweight $38 → $40
Feb-03-12Downgrade MKM Partners Buy → Neutral $42 → $40
Nov-29-11Initiated MKM Partners Buy $38
Sep-14-11Reiterated Barclays Capital Overweight $41 → $38
May-16-11Reiterated UBS Buy $40 → $42
Feb-04-11Reiterated UBS Buy $42 → $40
Jan-24-11Reiterated Deutsche Bank Buy $48 → $43
Jan-24-11Reiterated Barclays Capital Overweight $43 → $41
Nov-24-14 03:57PM  Merck, Iowa firm sign Ebola vaccine licensing deal AP
11:25AM  Merck buys the rights to an experimental Ebola vaccine at Fortune
11:15AM  Merck Obtains Rights to Ebola Vaccine at The Wall Street Journal
08:16AM  Merck buys rights to NewLink's experimental Ebola vaccine Reuters
08:06AM  Merck to Collaborate With NewLink on Experimental Ebola Vaccine at Bloomberg
08:00AM  Merck Submits New Drug Application to the Japanese Pharmaceuticals and Medical Devices Agency for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes Business Wire
07:56AM  Merck, NewLink to collaborate on Ebola vaccine at MarketWatch
07:30AM  Merck and NewLink Genetics Enter Into Licensing and Collaboration Agreement for Investigational Ebola Vaccine GlobeNewswire
07:30AM  Merck and NewLink Genetics Enter Into Licensing and Collaboration Agreement for Investigational Ebola Vaccine Business Wire
Nov-22-14 05:00AM  Motley Fool: Pundits pandering your wealth away at USA TODAY
Nov-21-14 01:47PM  You Should Hold Merck According to Dividends Generation Gurufocus
09:55AM  Today's Momo Momentum Stock Is Merck (MRK) at TheStreet
08:13AM  Do The IMPROVE-IT Results Offer Promise For Anacetrapib, Another Merck Heart Drug? at Forbes
07:20AM  Europe gives green light to AbbVie hepatitis C medicine, others Reuters
Nov-20-14 04:00PM  Dow, S&P close at records; Intel up 4% at CNBC
03:58PM  NewLink in Talks With Merck on Producing Ebola Vaccine at Bloomberg
03:30PM  Regeneron & Sanofi Present Positive Data on PCSK9 Drug Zacks
11:44AM  Sanofi's Bullish Pipeline Forecast Underwhelms Street at Investor's Business Daily
08:49AM  New 'Hutch' Director Aims To Push Toward Cancer Cures Based On The Immune System at Forbes
Nov-19-14 02:35PM  Will The IMPROVE-IT Results Impact The Thinking Of The FDA And Payers On LDL-Cholesterol Lowering Drugs? at Forbes
11:07AM  Stocks Boosted by Merck's Vytorin Data at Barrons.com
Nov-18-14 05:15PM  Merck KGaA Ties Up with Pfizer on Immuno-oncology Deal Zacks
01:04PM  MERCK & CO. INC. Financials EDGAR Online Financials
12:15PM  European Companies Poised to Pounce on U.S. Assets --- Moody's at The Wall Street Journal
09:45AM  REUTERS AMERICA NEWS PLAN FOR TUESDAY NOV 18 Reuters
12:41AM  Mercks Zetia Shows Modest Benefit in Reducing Heart Attacks at The Wall Street Journal
Nov-17-14 08:39PM  Actavis to buy Botox maker Allergan for $66B at USA TODAY
06:00PM  Cramer: Their weakness is our strength CNBC
05:42PM  [$$] Zetia Shows Modest Benefit in Reducing Heart Attacks at The Wall Street Journal
05:30PM  Merck Updates on Anti-PD-1 Drug Keytruda Phase II Study Zacks
05:01PM  Actavis to spend $66 billion on Allergan AP
04:40PM  The 10 biggest R&D spenders worldwide at Fortune
04:37PM  Taking Stock: Winners and Losers, Stock of the Day at Bloomberg
04:00PM  Stocks little moved; S&P 500 at record-high close at CNBC
02:53PM  Will Merck (MRK) Stock Be Helped Today by Zetia Study? at TheStreet
01:41PM  Long-Awaited Study Boosts Merck, Could Be Good News for Regeneron, Amgen at Barrons.com
01:35PM  Merck Drug Works: Vytorin Study Proves Successful at Investor's Business Daily
01:03PM  Midday movers: Allergan, CarMax, CBS & more at CNBC
11:45AM  VYTORIN® (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study Business Wire
11:45AM  Surprise! Vytorin Works. Here Are Five Things You Should Know. at Forbes
11:37AM  Merck's Zetia cuts heart attack, stroke risk in long-awaited study Reuters
11:32AM  IMPROVE-IT Meets Endpoint And Demonstrates Real But Modest Clinical Benefit For Ezetimibe at Forbes
11:05AM  Pfizer, Germanys Merck strike deal to develop cancer tumor treatment at MarketWatch
10:17AM  [$$] Pfizer, Germany's Merck to Develop Tumor Treatment at The Wall Street Journal
10:04AM  Pfizer Strikes Pact with Merck After Abandoning AstraZeneca TheStreet
10:04AM  Pfizer Strikes Immuno-oncology Pact with Merck After Abandoning AstraZeneca at TheStreet
09:55AM  Cramer's Stop Trading: Hotel caution? CNBC
09:24AM  Cramer's Mad Dash: Pfizer's direction CNBC
09:16AM  Allergan and Actavis close to deal; Halliburton and Baker Hughes make it official; DreamWorks tumbles as Hasbro talks flop Hot Stock Minute
09:10AM  Study lifts cloud over heart drugs Zetia, Vytorin AP
08:46AM  Merck says long-term cholesterol drug study met primary endpoint Reuters
08:41AM  Mercks Vytorin First Cholesterol Drug to Further Cut Heart Risk at Bloomberg
08:39AM  After Years Under Attack, Merck's Vytorin Proves Effective at Forbes
08:30AM  Merck Announces that IMPROVE-IT Achieved Primary Endpoint; Data to be Presented at American Heart Association Scientific Sessions Today Business Wire
05:47AM  US stocks seen lower after Japan enters recession at CNBC
05:37AM  Pfizer dampens Astra bid hopes with German Merck cancer deal Reuters
03:10AM  German Merck, Pfizer in cancer immunotherapy deal Reuters
Nov-16-14 04:25AM  MSD Announces Positive Study Investigating the Use of Pembrolizumab Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma Business Wire
04:25AM  Merck Announces Positive Study Investigating the Use of KEYTRUDA® (pembrolizumab) Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma Business Wire
Nov-14-14 04:48PM  The 4 DJIA Stocks That Weighed Down Fridays Market at 24/7 Wall St.
01:20PM  Merck KGaA Q3 Earnings Rise Y/Y, 2014 View Upgraded Zacks
09:12AM  Up and Down the Ladder: The Latest Comings and Goings at Actavis, Alexion and at The Wall Street Journal
Nov-13-14 06:58PM  Which Health Care ETF Should You Buy? at Investor's Business Daily
03:48PM  Can Gilead Recover from 3Q? at Barrons.com
10:21AM  A Day Of Reckoning Approaches For Merck And Its Critics at Forbes
09:15AM  4 Top Pharmaceutical Companies Helping Combat Hepatitis C Near Epidemic at 24/7 Wall St.
06:52AM  [$$] Germany's Merck Nudges Sales Forecast Higher at The Wall Street Journal
06:07AM  Monte Paschi Posts 10th Straight Quarterly Loss at Bloomberg
02:35AM  Merck KGaA core earnings up 3 percent on AZ takeover Reuters
01:20AM  Merck KGaA Raises 2014 Forecast as Sales of Rebif Climb at Bloomberg
Nov-12-14 05:31PM  Gene study boosts interest in heart drug Zetia AP
05:00PM  Rare Mutation Mimicked by Mercks Zetia Cuts Heart Risk at Bloomberg
05:00PM  U.S. gene study raises hope for Merck cholesterol drug Zetia Reuters
09:45AM  Merck Braces for Study on Medicines Worth $4 Billion a Year at Bloomberg
08:40AM  Tuesdays Notable Options Activity Yahoo Finance Blogs
Nov-11-14 04:16PM  Dow, S&P 500 close at record on Veterans Day at CNBC
10:31AM  Would a Positive Result for the Vytorin Trial Really Help Merck? at The Wall Street Journal
09:00AM  AbbVie Hepatitis C Drug Cures 97% in Transplant Patients Study at Bloomberg
08:00AM  Merck Announces Results from Phase 2 Study of Investigational Chronic Hepatitis C Treatment Grazoprevir/Elbasvir in Genotype 1 Infected Treatment-Naïve and Difficult-to-Cure Patients Business Wire
01:11AM  [$$] Merck Filing Suggests Trial Results Wont Significantly Hurt Vytorin, Zetia at The Wall Street Journal
Nov-10-14 07:00PM  Merck down on hep C data Investor's Business Daily
06:00PM  Merck: 4-week Hepatitis C treatment too short CNBC
06:00PM  Cramer: Default to big themes CNBC
05:32PM  Merck Shares May Have Hit A Ceiling For The Most Recent Upside Move Benzinga
04:44PM  US STOCKS-Dow, S&P 500 end at record highs; transports jump Reuters
04:21PM  S&P, Dow again rise to record closes amid earnings at CNBC
03:45PM  Merck Reports Interim Data on Hepatitis C Virus Drug Zacks
03:32PM  Merck expects no writedowns for Zetia, Vytorin cholesterol drugs Reuters
02:49PM  US STOCKS-Wall Street inches up to new highs; transports jump Reuters
02:18PM  Dendreon declares bankruptcy CNBC
01:34PM  Business events scheduled for Tuesday AP
01:30PM  US STOCKS-Wall Street climbs to new highs; transports rally Reuters
01:26PM  [$$] Trial Results Not Expected to Hurt Merck's Vytorin, Zetia at The Wall Street Journal
12:57PM  Midday movers: Merck & Co., GoPro, Blackberry & more at CNBC
12:39PM  Merck, Dendreon miss out on health-care rally at MarketWatch
11:58AM  US STOCKS-Wall Street climbs modestly after three-week run Reuters
11:40AM  [video]Merck's Hepatitis C Study Falls Short, Its Loss Is Gilead's Gain at TheStreet
11:14AM  Merck Down On Hepatitis C Data; Gilead Rises at Investor's Business Daily
11:10AM  Hep C Patients Are Biggest Winners in Competitive Race for New Cures Yahoo Finance Blogs
11:06AM  US STOCKS-Wall Street edges higher after three-week run Reuters
Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. The company's Pharmaceutical segment offers human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of cardiovascular, diabetes and obesity, respiratory, women's health and endocrine, inflammatory and infectious diseases, oncology, ophthalmology, immunology, infectious diseases, and others. This segment also provides vaccines, including preventive pediatric, adolescent, and adult vaccines. Its Animal Health segment discovers, develops, manufactures, and markets animal health products comprising vaccines, antibiotics, and anti-inflammatory drugs for respiratory diseases, as well as products for the treatment of fertility disorders. The company's Consumer Care segment develops, manufactures, and sells over-the-counter products consisting of non-drowsy antihistamines; decongestant-free cold/flu medicine for people with high blood pressure; nasal decongestant sprays; and products for occasional constipation, frequent heartburn, and overactive bladder in women; foot care products, including topical antifungal, and foot and sneaker odor/wetness products; and sun care products, such as sun care lotions, sprays, and dry oils. The company serves drug wholesalers and retailers, hospitals, government agencies, physicians, physician distributors, veterinarians, animal producers, food chain and mass merchandiser outlets, club stores, and specialty channels, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. It has collaborations with AstraZeneca LP, Pfizer Inc., Samsung Bioepis Co., Ltd., Sanofi Pasteur S.A., and Sysmex Inostics GmbH. The company was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FRAZIER KENNETH CChairman, President & CEONov 10Option Exercise34.2012,875440,272354,420Nov 10 04:36 PM
FRAZIER KENNETH CChairman, President & CEONov 10Sale57.9810,000579,784344,420Nov 10 04:36 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthNov 02Option Exercise0.004,38704,387Nov 03 04:46 PM
FRAZIER KENNETH CChairman, President & CEOOct 10Option Exercise34.2012,875440,272351,440Oct 14 09:05 AM
FRAZIER KENNETH CChairman, President & CEOOct 10Sale59.739,895591,033341,545Oct 14 09:05 AM
FRAZIER KENNETH CChairman, President & CEOSep 10Option Exercise34.2012,875440,272348,379Sep 10 01:53 PM
FRAZIER KENNETH CChairman, President & CEOSep 10Sale60.489,814593,592338,565Sep 10 01:53 PM
FRAZIER KENNETH CChairman, President & CEOAug 11Option Exercise34.2012,875440,272345,562Aug 12 09:01 AM
FRAZIER KENNETH CChairman, President & CEOAug 11Sale57.0010,058573,306335,504Aug 12 09:01 AM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerAug 04Option Exercise45.3823,4001,061,82042,844Aug 05 09:56 AM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerAug 04Sale56.6428,6691,623,72014,175Aug 05 09:56 AM
REPRESAS CARLOS EDirectorAug 01Option Exercise35.195,000175,9505,500Aug 05 10:16 AM
FRAZIER KENNETH CChairman, President & CEOJul 10Option Exercise34.2012,876440,307351,474Jul 10 03:47 PM
FRAZIER KENNETH CChairman, President & CEOJul 10Sale58.039,987579,545341,487Jul 10 03:47 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 07Option Exercise30.01180,0475,403,278273,611Jul 08 02:16 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 07Sale59.16180,04710,650,93293,564Jul 08 02:16 PM
Deese Willie AExe V-P & Pres. MMDJun 27Option Exercise27.8572,2902,013,164178,512Jun 30 04:23 PM
Deese Willie AExe V-P & Pres. MMDJun 27Sale58.2672,2904,211,254106,222Jun 30 04:23 PM
Schechter Adam HEVP & Pres-Global Human HealthMay 14Sale55.9110,527588,5840May 14 02:48 PM
FRAZIER KENNETH CChairman, President & CEOMay 09Option Exercise34.2012,876440,307345,927May 13 03:56 PM
FRAZIER KENNETH CChairman, President & CEOMay 09Sale55.0010,220562,100335,707May 13 03:56 PM
Schechter Adam HEVP & Pres-Global Human HealthMay 04Option Exercise0.0019,147019,147May 06 04:03 PM
Golestani ClarkEVP & Chief Info OfficerMay 04Option Exercise0.002,05109,278May 06 04:02 PM
GRADDICK WEIR MIRIAN MExe V-P, HRMay 04Option Exercise0.009,300098,387May 06 04:02 PM
Heller Bridgette PExe.VP & Pres.Con.Hlth.CareMay 04Option Exercise0.005,470038,311May 06 04:02 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 04Option Exercise0.004,240011,999May 06 04:02 PM
Kuhlik Bruce NExe V-P & Gen CounselMay 04Option Exercise0.009,8470132,660May 06 04:02 PM
Rosenblatt MichaelExec V-P & Chief Med OfficerMay 04Option Exercise0.004,103026,720May 06 04:02 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerMay 04Option Exercise0.004,103020,828May 06 04:01 PM
Deese Willie AExe V-P & Pres. MMDMay 04Option Exercise0.007,6590109,671May 06 04:01 PM
FRAZIER KENNETH CChairman, President & CEOMay 04Option Exercise0.0041,0280351,522May 06 04:01 PM
HARRISON WILLIAM B JRDirectorApr 25Option Exercise47.235,000236,1506,400Apr 29 11:36 AM
FRAZIER KENNETH CChairman, President & CEOApr 10Option Exercise34.2012,876440,307320,541Apr 11 09:53 AM
FRAZIER KENNETH CChairman, President & CEOApr 10Sale57.2410,047575,108310,494Apr 11 09:53 AM
Kuhlik Bruce NExe V-P & Gen CounselApr 04Option Exercise39.90145,2255,794,929267,070Apr 04 05:07 PM
Kuhlik Bruce NExe V-P & Gen CounselApr 04Sale56.43145,2258,195,164121,845Apr 04 05:07 PM
Golestani ClarkEVP & Chief Info OfficerFeb 14Option Exercise48.246,375307,53012,036Feb 14 05:11 PM
Golestani ClarkEVP & Chief Info OfficerFeb 14Sale55.475,990332,2766,046Feb 14 05:11 PM
Heller Bridgette PExe.VP & Pres.Con.Hlth.CareFeb 13Option Exercise36.5649,7501,818,86071,457Feb 14 11:17 AM
Heller Bridgette PExe.VP & Pres.Con.Hlth.CareFeb 13Sale55.0443,8702,414,57027,587Feb 14 11:17 AM
Canan JohnSr.V-P Finc-Global ControllerFeb 11Option Exercise48.2410,000482,40020,697Feb 11 05:07 PM
FRAZIER KENNETH CChairman, President & CEOFeb 11Option Exercise48.2445,0002,170,800304,349Feb 11 05:34 PM
Schechter Adam HEVP & Pres-Global Human HealthFeb 11Option Exercise47.6518,000857,70518,000Feb 13 10:12 AM
Schechter Adam HEVP & Pres-Global Human HealthFeb 11Sale55.6118,0001,000,9350Feb 13 10:12 AM
Canan JohnSr.V-P Finc-Global ControllerFeb 11Sale55.7010,000557,00210,697Feb 11 05:07 PM
FRAZIER KENNETH CChairman, President & CEOFeb 11Sale54.5241,5202,263,683262,829Feb 11 05:34 PM
WEEKS WENDELL PDirectorFeb 10Option Exercise47.235,000236,1505,100Feb 11 03:41 PM
WENDELL PETER CDirectorFeb 10Option Exercise47.235,000236,1506,000Feb 11 03:48 PM
Deese Willie AExe V-P & Pres. MMDFeb 10Option Exercise48.2420,000964,800156,049Feb 11 03:54 PM
Deese Willie AExe V-P & Pres. MMDFeb 10Sale54.6850,0002,734,155106,049Feb 11 03:54 PM
WENDELL PETER CDirectorFeb 10Sale54.445,000272,1931,000Feb 11 03:48 PM
WEEKS WENDELL PDirectorFeb 10Sale54.265,000271,283100Feb 11 03:41 PM
Deese Willie AExe V-P & Pres. MMDJan 27Option Exercise47.7930,0001,433,700136,049Jan 28 10:09 AM